The AHEAD-MERIT trial will take place in 15 hospitals, targeting patients with aggressive HPV-associated cancers with an innovative vaccine.
Gabriel Dumitrache
International
Foto: Shutterstock
Always see our news on Google
The AHEAD-MERIT clinical trial will take place in 15 hospitals in England, targeting patients with aggressive human papillomavirus (HPV)-associated cancers. These cancers have high rates of recurrence and poor survival. The vaccine being developed targets proteins commonly found in HPV-associated head and neck cancer. The health secretary declared the initiative a "huge victory" and NHS England is working with BioNTech to identify eligible patients. This is the third trial under the NHS Cancer Vaccine Launch Pad, which has already supported 550 patients.
Sources
Latest News
16:44
CNAIR has submitted the documentation for the revision of the Environmental Agreement for section 2 Boița - Cornetu of the Sibiu - Pitești highway.
16:38
China has decided to abandon earlier the adapted version of Windows 10 used in state institutions, in favor of local technologies.
16:38
The European Union condemns the actions of the United States against the International Criminal Court.
16:35
Aurelian Gogulescu, the president of the Prahova Chamber of Commerce and Industry, has passed away, according to the family's announcement.
16:23
Andras Baka, at the age of 73, has taken over the presidency of Hungary
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
.webp)
